SG 3 0020
Alternative Names: SG-3-0020Latest Information Update: 22 Nov 2021
At a glance
- Originator Second Genome
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Nov 2021 Second Genome plans clinical trial in cancer in 2022
- 07 Oct 2021 Pharmacodynamics data from preclinical studies in cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2021 (AACR-NCI-EORTC-2021)
- 07 Oct 2021 SG 3 0020 is available for licensing as of 07 Oct 2021. www.secondgenome.com